Haemonetics (HAE) Accumulated Expenses (2010 - 2026)

Haemonetics has reported Accumulated Expenses for 17 years, with the latest figure at $68.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 14.76% year-over-year to $68.2 million; the trailing twelve-month figure through Mar 2026 stood at $68.2 million (up 14.76% YoY), and the FY2026 full-year result was $68.2 million, up 14.76% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $68.2 million, up from $52.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $80.7 million in Q1 2024, with the low at $30.4 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $49.8 million, with a median of $48.4 million recorded in 2022.
• Year-over-year, Accumulated Expenses soared 33.64% in 2022 and decreased 26.37% in 2025.
• Tracing HAE's Accumulated Expenses over 5 years: stood at $52.2 million in 2022, then climbed by 12.61% to $58.8 million in 2023, then slipped by 21.83% to $45.9 million in 2024, then gained by 13.42% to $52.1 million in 2025, then surged by 30.89% to $68.2 million in 2026.
• The last three Accumulated Expenses figures came in at $68.2 million (Q1 2026), $52.1 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.

Peer Comparison